In the case of STAT3, which is involved in multiple signaling pathways related to GBM tumor progression and immune response7, previous studies have demonstrated positive therapeutic effects in vitro and in peripheral tumors, but small molecule inhibitors of STAT3 proved to be ineffective in intracranial models of the disease6. The gene discussed is STAT3; the disease is neoplasm.